Standard BioTools Announces Conference Call and Webcast for Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
14 Fevereiro 2024 - 10:30AM
Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose –
Unleashing tools to accelerate breakthroughs in human health™ –
today announced that it will report fourth quarter and full year
2023 financial results on Wednesday, February 28, 2024, after
the close of the market.
The Company’s management will host a conference call and webcast
at 1:30 p.m. PT, 4:30 p.m. ET, on February 28, 2024, to
discuss fourth quarter and full year 2023 financial results and
operational progress. A press release including the financial
results will be publicly distributed before the call.
Individuals interested in listening to the conference call may
do so by dialing:
US domestic callers: (888) 346-3970Outside US
callers: (412) 902-4297
Live audio of the webcast will be available online on the
Investor Relations page of the Company’s website at Events
& Presentations. The webcast will be archived and available on
Standard BioTools™ Investor Relations page
at investors.standardbio.com.
About Standard BioTools Inc.
Standard BioTools Inc. (Nasdaq:LAB), previously known as
Fluidigm Corporation, is driven by a bold purpose – Unleashing
tools to accelerate breakthroughs in human health. Standard
BioTools has an established portfolio of essential, standardized
next-generation technologies that help biomedical researchers
develop medicines faster and better. As a leading solutions
provider, the company provides reliable and repeatable insights in
health and disease using its proprietary mass cytometry and
microfluidics technologies, which help transform scientific
discoveries into better patient outcomes. Standard BioTools works
with leading academic, government, pharmaceutical, biotechnology,
plant and animal research and clinical laboratories worldwide,
focusing on the most pressing needs in translational and clinical
research, including oncology, immunology and immunotherapy. Learn
more at standardbio.com or connect with us on X, Facebook®,
LinkedIn and YouTube™. Standard BioTools, the Standard BioTools
logo, Fluidigm, the Fluidigm logo, “Unleashing tools to accelerate
breakthroughs in human health,” Imaging Mass Cytometry, IMC,
Hyperion, Hyperion XTi and XTi are trademarks and/or registered
trademarks of Standard BioTools Inc. or its affiliates in the
United States and/or other countries. All other trademarks are the
sole property of their respective owners. Standard
BioTools products are provided for Research Use Only. Not for use
in diagnostic procedures.
Available Information
Standard BioTools uses its website (standardbio.com), investor
site (investors.standardbio.com), corporate X account
(@Standard_BioT), Facebook page (facebook.com/StandardBioT), and
LinkedIn page (linkedin.com/company/standard-biotools) as channels
of distribution of information about its products, its planned
financial and other announcements, its attendance at upcoming
investor and industry conferences and other matters. Such
information may be deemed material information, and Standard
BioTools may use these channels to comply with its disclosure
obligations under Regulation FD. Therefore, investors should
monitor Standard BioTools website and its social media accounts in
addition to following its press releases, SEC filings, public
conference calls and webcasts.
Investor Contact:
David Holmesir@standardbio.com
Standard BioTools (NASDAQ:LAB)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Standard BioTools (NASDAQ:LAB)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024